Oxford Gene Technology (IP) Limited

Oxford Gene Technology (OGT) is a precision genomics company specializing in molecular diagnostics for clinical and research laboratories. The company develops and manufactures hybridization-based FISH (fluorescence in situ hybridization), NGS (next-generation sequencing), and array-based genomic solutions for haematological malignancies, solid tumours, cytogenetics, and rare disease detection. OGT's primary product portfolio includes CytoCell FISH probes, SureSeq NGS panels, and CytoSure arrays. Recent offerings include the SureSeq Myeloid MRD Plus NGS Panel for minimal residual disease detection in acute myeloid leukaemia, and the FDA-authorized CytoCell KMT2A Breakapart FISH Probe Kit PDx as a companion diagnostic for KMT2A-rearranged acute leukaemia. OGT provides end-to-end support from assay design through clinical implementation, including precision medicine partnering for clinical trial and companion diagnostic development. The company serves clinical diagnostic laboratories, research institutions, and oncology centers globally, with established partnerships and customer bases across North America, Europe, and international markets. OGT's technical support is provided by personnel with laboratory backgrounds, supporting implementation of test workflows and biomarker interrogation. The company holds FDA authorizations for companion diagnostics and operates under clinical laboratory standards for genomic testing.